Lipids & metabolic liver disease
Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
Authors' conclusion
Among people with diabetes and hepatic steatosis, GLP1-RA use was associated with a lower risk of liver disease progression and a lower risk of MACE/death compared to DPP4i use. In people with MASLD, a holistic approach that seeks to lower MACE/death, beyond lowering liver disease progression alone, should be prioritised.
Study context
- Population
- People with non-alcoholic hepatic steatosis (and diabetes) who initiated GLP-1 RA or DPP-4i between 1 October 2005 and 30 September 2021, Department of Veteran Affairs58,157 matched pairs
- Exposure
- GLP-1 RA vs DPP-4i
- Outcome
- (1) Liver disease progression and (2) major acute cardiovascular events (MACE) and death from any cause (MACE/death)
Methodological detailspropensity score matched on 73 baseline characteristics, national Department of Veteran Affairs data
- Propensity score matched on 73 baseline characteristics
- National Department of Veteran Affairs data
Original publication
Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes. Diabetes Obes Metab. Published 30 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →